Columbia Laboratories acquires Molecular Profiles in multimillion-dollar deal.
Columbia Laboratories has acquired Molecular Profiles, a UK-based pharmaceutical development services company, for approximately $25 million.
This acquisition was unanimously approved by the boards of directors of both companies and received the approval of Molecular Profiles’ shareholders. No further approvals are anticipated to be required.
According to the company, Molecular Profiles’ recorded approximately $9 million in revenues for its fiscal year ended July 31, 2013.
Source: Columbia Laboratories
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.